|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.13 USD | -1.03% |
|
+2.01% | +6.50% |
| 18/04 | Nuvalent, Inc - Nuvalent anticipates U.S. commercial launch of Zidesamtinib in 2026 | RE |
| 18/04 | Nuvalent Inc Presents New Clinical and Preclinical Data for Zidesamtinib | CI |
| Capitalization | 842.22Cr 716.56Cr 657.22Cr 623.52Cr 1.15TCr 79TCr 1.18TCr 7.72TCr 3.04TCr 38TCr 3.16TCr 3.09TCr 1,34300Cr | P/E ratio 2026 * |
-18.8x | P/E ratio 2027 * | -24.4x |
|---|---|---|---|---|---|
| Enterprise value | 755.97Cr 643.18Cr 589.91Cr 559.66Cr 1.03TCr 71TCr 1.05TCr 6.93TCr 2.73TCr 34TCr 2.84TCr 2.78TCr 1,20500Cr | EV / Sales 2026 * |
547x | EV / Sales 2027 * | 40.5x |
| Free-Float |
85.54% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nuvalent, Inc.
| 1 day | -1.03% | ||
| 1 week | +2.01% | ||
| Current month | +4.57% | ||
| 1 month | +13.04% | ||
| 3 months | -1.75% | ||
| 6 months | +10.24% | ||
| Current year | +6.50% |
| 1 week | 101.79 |  | 108.82 |
| 1 month | 93.91 | | 108.82 |
| Current year | 93.91 | | 113.02 |
| 1 year | 63.56 | | 113.02 |
| 3 years | 33.03 | | 113.51 |
| 5 years | 7.09 | | 113.51 |
| 10 years | 7.09 | | 113.51 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Porter
CEO | Chief Executive Officer | 50 | 01/01/2017 |
Alexandra Balcom
DFI | Director of Finance/CFO | 42 | 01/01/2021 |
Henry Pelish
CTO | Chief Tech/Sci/R&D Officer | - | 11/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
James Porter
BRD | Director/Board Member | 50 | 01/02/2020 |
Cameron Wheeler
CHM | Chairman | 47 | 01/02/2017 |
Joseph Pearlberg
BRD | Director/Board Member | 62 | 01/01/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.03% | +2.01% | +53.15% | +210.16% | 850.95Cr | |
| -3.00% | -2.64% | +30.94% | +94.45% | 5.19TCr | |
| -1.21% | -7.51% | +82.87% | +28.98% | 4.43TCr | |
| -1.29% | -8.10% | +102.82% | +673.77% | 3.08TCr | |
| +6.09% | +13.40% | +9.62% | -5.65% | 2.66TCr | |
| +5.02% | +26.52% | +4.60% | +1,580.25% | 1.95TCr | |
| -0.40% | -4.81% | +63.43% | -29.35% | 1.88TCr | |
| +1.98% | +1.56% | +69.34% | +251.41% | 1.73TCr | |
| -2.42% | -6.02% | +34.11% | -37.90% | 1.72TCr | |
| -0.58% | -4.12% | +65.87% | - | 1.51TCr | |
| Average | +0.34% | +3.36% | +51.68% | +307.35% | 2.5TCr | |
| Weighted average by Cap. | -0.07% | +1.32% | +52.87% | +266.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.38Cr 1.18Cr 1.08Cr 1.02Cr 1.89Cr 129.23Cr 1.93Cr 13Cr 4.98Cr 62Cr 5.18Cr 5.07Cr 220.22Cr | 18Cr 16Cr 14Cr 14Cr 25Cr 1.71TCr 26Cr 167.71Cr 66Cr 821.62Cr 69Cr 67Cr 2.92TCr |
| Net income | -44Cr -38Cr -35Cr -33Cr -61Cr -4.15TCr -62Cr -406.75Cr -160.08Cr -1.99TCr -166.5Cr -163.07Cr -7.08TCr | -35Cr -30Cr -27Cr -26Cr -48Cr -3.27TCr -49Cr -320.75Cr -126.23Cr -1.57TCr -131.3Cr -128.59Cr -5.58TCr |
| Net Debt | -86Cr -73Cr -67Cr -64Cr -117.74Cr -8.07TCr -120.35Cr -790.36Cr -311.05Cr -3.87TCr -323.54Cr -316.86Cr -14TCr | -100.06Cr -85Cr -78Cr -74Cr -136.58Cr -9.36TCr -139.62Cr -916.87Cr -360.84Cr -4.49TCr -375.32Cr -367.58Cr -16TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/26/21 | 107.13 $ | -1.03% | 7,87,206 |
| 20/26/20 | 108.24 $ | +0.59% | 4,02,906 |
| 17/26/17 | 107.61 $ | +3.61% | 7,72,833 |
| 16/26/16 | 103.86 $ | -0.85% | 5,91,160 |
| 15/26/15 | 104.75 $ | -0.26% | 6,19,093 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NUVL Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition